LEXICON PHARMACEUTICALS, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value
LEXICON PHARMACEUTICALS, INC. (LXRX) had Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value of $0 as of 2018-12-31, per its 10-K filed 2019-03-15.
Discontinued › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue · last filed 2019-03-15
- 2018-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $0.00.
- 2017-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $18.91M; Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value as first filed $0.00.
- 2017-09-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $0.00.
- 2017-06-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $0.00.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value as first filed |
|---|---|---|
| 2018-12-31 | $0.00 10-K · filed 2019-03-15 | |
| 2017-12-31 | $18.91M 10-K · filed 2019-03-15 | $0.00 10-K · filed 2018-03-01 |
| 2017-09-30 | $0.00 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $0.00 10-Q · filed 2017-08-01 | |
| 2017-03-31 | $0.00 10-Q · filed 2017-05-04 | |
| 2016-12-31 | $22.82M 10-K · filed 2019-03-15 | $18.91M 10-K · filed 2017-03-06 |
| 2016-09-30 | $18.91M 10-Q · filed 2017-11-08 | |
| 2016-06-30 | $24.26M 10-Q · filed 2017-08-01 | |
| 2016-03-31 | $23.78M 10-Q · filed 2017-05-04 | |
| 2015-12-31 | $22.82M 10-K · filed 2018-03-01 | |
| 2015-09-30 | $22.03M 10-Q · filed 2016-11-07 | |
| 2015-06-30 | $18.63M 10-Q · filed 2016-08-04 | |
| 2015-03-31 | $18.64M 10-Q · filed 2016-05-05 | |
| 2015-01-01 | $17.64M 10-K · filed 2018-03-01 | |
| 2014-12-31 | $17.64M 10-K · filed 2017-03-06 | |
| 2014-09-30 | $28.23M 10-Q · filed 2015-11-09 | |
| 2014-06-30 | $29.30M 10-Q · filed 2015-08-07 | |
| 2014-03-31 | $28.85M 10-Q · filed 2015-05-05 | |
| 2014-01-01 | $27.71M 10-K · filed 2017-03-06 | |
| 2013-12-31 | $27.71M 10-K · filed 2016-03-11 | |
| 2013-09-30 | $33.00M 10-Q · filed 2014-11-06 | |
| 2013-06-30 | $31.66M 10-Q · filed 2014-08-07 | |
| 2013-03-31 | $31.18M 10-Q · filed 2014-05-08 | |
| 2012-12-31 | $29.92M 10-K · filed 2016-03-11 | |
| 2012-09-30 | $30.12M 10-Q · filed 2013-11-12 | |
| 2012-06-30 | $59.28M 10-Q · filed 2013-08-01 | |
| 2012-03-31 | $57.11M 10-Q · filed 2013-05-10 | |
| 2011-12-31 | $55.03M 10-K · filed 2015-03-12 | |
| 2011-09-30 | $53.47M 10-Q · filed 2012-11-07 | |
| 2011-06-30 | $51.13M 10-Q · filed 2012-08-02 | |
| 2010-12-31 | $48.27M 10-K · filed 2014-03-07 | |
| 2009-12-31 | $0.00 10-K · filed 2013-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |